Bachmann makes serious blunder on HPV vaccine

Article

In a broadcast interview this morning, Rep. Michele Bachmann (R-Minn.) suggested the human papillomavirus (HPV) vaccine, mandated by Texas Gov. Rick Perry in 2007, caused a girl to suffer "mental retardation."Talking with Matt Lauer on NBC's Today show, Bachmann said, "A mother...told me that her little daughter took that vaccine, that injection, and she suffered from mental retardation thereafter. The mother was crying... This is the very real concern and people have to draw their own conclusions."In 2007, Perry signed an executive order requiring sixth-grade girls to be inoculated against HPV, which is the leading cause of cervical cancer. He later said it was a mistake to act unilaterally, and the executive order was eventually overturned by the Texas Legislature.Let's Be Clear

There is no evidence that the FDA-approved HPV vaccines (there are two, Cervarix and Gardasil) cause mental retardation. In fact, the Centers for Disease Control reports that both vaccines have been tested in thousands of people around the world and no serious side effects have been reported. Side effects of approved drugs continue to be monitored and reported, and if the side effects are great or frequent enough, a drug will be pulled from the market. The few anecdotal stories of serious side effects from these vaccines have not been validated.Just the Facts, Ma'am

• HPV is the main cause of cervical cancer in women

• About 11,000 new cervical cancer cases are diagnosed each year in the U.S.

• About 4,000 American women die each year from cervical cancer

• Both vaccines are very effective against HPV types 16 and 18, which cause most cervical cancers

• Michelle Bachmann is a tax attorney, not a medical professionalAs the campaign rhetoric continues to heat up, it's important to separate fact from fiction. HPV-related cancers are expected to rise significantly in the next decade, according to the National Cancer Institute. We need to develop a public health response that's based on actual science, not hysteria and hyperbole.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content